Glycaemic control efficacy of switching from dipeptidyl peptidase-4 inhibitors to oral semaglutide in subjects with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 2 study).

Furusawa S, Nomoto H, Yokoyama H, Suzuki Y, Tsuzuki A, Takahashi K, Miya A, Kameda H, Cho KY, Takeuchi J, Nagai S, Taneda S, Kurihara Y, Nakamura A, Atsumi T

Diabetes, obesity & metabolism11 Dec 2023Cited by 15 (Europe PMC)

PMID38073422DOI10.1111/dom.15393PepBankPUB-38073422

Publisher page PubMedAsk about this study

Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, switching from a DPP-4 inhibitor to oral semaglutide lowered HbA1c more than continuing the DPP-4 inhibitor at week 24.
In plain wordsIn adults with type 2 diabetes, switching to oral semaglutide lowered HbA1c more than staying on a DPP-4 inhibitor.
Peptide
Semaglutide
Outcome
DecreaseHbA1c change at week 24
Study
n = 157
Comparator
DPP-4 inhibitor continuation
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
3-14 mg/day · oral · 24 weeksAs given in this study (human).
Measurements
HbA1c change
−0.65 not stated
switch to semaglutide
HbA1c change
0.05 not stated
DPP-4i continuation
Source sentences
Summary
Improvement in HbA1c at week 24 was significantly greater when switching to semaglutide compared with DPP-4i continuation [-0.65 (95% confidence interval: -0.79, -0.51) vs. +0.05 (95% confidence interval: -0.07, 0.16) (p < .001)].
2 context sentences(design, population, supporting numbers)
Summary · context
Consequently, 82 participants in the DPP-4i group and 75 participants in the semaglutide group completed the study and were included in the analysis.
Summary · context
In this multicentre, open-label, prospective, randomized, parallel-group comparison study, participants receiving DPP-4is were either switched to oral semaglutide (3-14 mg/day) or continued on DPP-4is.
Report a problemFND-3807342201
02HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, body weight improved significantly more after switching to oral semaglutide than with DPP-4 inhibitor continuation.
In plain wordsIn adults with type 2 diabetes, body weight improved more after switching to oral semaglutide than on a DPP-4 inhibitor.
Peptide
Semaglutide
Outcome
DecreaseBody weight change
Study
n = 157
Comparator
DPP-4 inhibitor continuation
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
3-14 mg/day · oral · 24 weeksAs given in this study (human).
Source sentences
Summary
Body weight, lipid profiles and liver enzymes were significantly improved
2 context sentences(design, population, supporting numbers)
Summary · context
Consequently, 82 participants in the DPP-4i group and 75 participants in the semaglutide group completed the study and were included in the analysis.
Summary · context
In this multicentre, open-label, prospective, randomized, parallel-group comparison study, participants receiving DPP-4is were either switched to oral semaglutide (3-14 mg/day) or continued on DPP-4is.
Report a problemFND-3807342202
03HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, lipid profiles improved significantly more after switching to oral semaglutide than with DPP-4 inhibitor continuation.
In plain wordsIn adults with type 2 diabetes, blood fat levels improved more after switching to oral semaglutide than on a DPP-4 inhibitor.
Peptide
Semaglutide
Outcome
Not applicableLipid profile change
Study
n = 157
Comparator
DPP-4 inhibitor continuation
Analysis
Secondary
Outcome group
Lipids · Metabolic and weight
Studied dose
3-14 mg/day · oral · 24 weeksAs given in this study (human).
Source sentences
Summary
Body weight, lipid profiles and liver enzymes were significantly improved in the semaglutide group than in the DPP-4i continuation group.
2 context sentences(design, population, supporting numbers)
Summary · context
Consequently, 82 participants in the DPP-4i group and 75 participants in the semaglutide group completed the study and were included in the analysis.
Summary · context
In this multicentre, open-label, prospective, randomized, parallel-group comparison study, participants receiving DPP-4is were either switched to oral semaglutide (3-14 mg/day) or continued on DPP-4is.
Report a problemFND-3807342203
04HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, liver enzymes improved significantly more after switching to oral semaglutide than with DPP-4 inhibitor continuation.
In plain wordsIn adults with type 2 diabetes, liver enzyme levels improved more after switching to oral semaglutide than on a DPP-4 inhibitor.
Peptide
Semaglutide
Outcome
DecreaseLiver enzyme change
Study
n = 157
Comparator
DPP-4 inhibitor continuation
Analysis
Secondary
Outcome group
Liver fat and liver function · Liver
Studied dose
3-14 mg/day · oral · 24 weeksAs given in this study (human).
Source sentences
Summary
Body weight, lipid profiles and liver enzymes were significantly improved in the semaglutide group than in the DPP-4i continuation group.
2 context sentences(design, population, supporting numbers)
Summary · context
Consequently, 82 participants in the DPP-4i group and 75 participants in the semaglutide group completed the study and were included in the analysis.
Summary · context
In this multicentre, open-label, prospective, randomized, parallel-group comparison study, participants receiving DPP-4is were either switched to oral semaglutide (3-14 mg/day) or continued on DPP-4is.
Report a problemFND-3807342204
05HumanRandomized controlled trialOther
In adults with type 2 diabetes switched to oral semaglutide, higher baseline HbA1c and HOMA2-R were independently associated with greater HbA1c improvement.
In plain wordsIn adults with type 2 diabetes switched to oral semaglutide, higher starting HbA1c and more insulin resistance were linked to bigger HbA1c improvement.
Peptide
Semaglutide
Outcome
Not applicableFactors associated with HbA1c improvement
Study
n = 75
Analysis
Exploratory
Outcome group
Glycemic control · Metabolic and weight
Studied dose
3-14 mg/day · oral · 24 weeksAs given in this study (human).
Source sentences
Summary
Multiple linear regression analysis revealed that baseline HbA1c and homeostasis model assessment 2-R were independently associated with HbA1c improvement after switching to semaglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
Consequently, 82 participants in the DPP-4i group and 75 participants in the semaglutide group completed the study and were included in the analysis.
Summary · context
In this multicentre, open-label, prospective, randomized, parallel-group comparison study, participants receiving DPP-4is were either switched to oral semaglutide (3-14 mg/day) or continued on DPP-4is.
Report a problemFND-3807342205
06HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes switched to oral semaglutide, seven participants stopped the drug because of gastrointestinal symptoms.
In plain wordsIn adults with type 2 diabetes switched to oral semaglutide, seven people stopped it because of stomach or bowel symptoms.
Peptide
Semaglutide
Outcome
Not applicableDiscontinuation because of gastrointestinal symptoms
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
3-14 mg/day · oral · 24 weeksAs given in this study (human).
Source sentences
Summary
Seven participants in the semaglutide group discontinued medication because of gastrointestinal symptoms.
1 context sentence(design, population, supporting numbers)
Summary · context
In this multicentre, open-label, prospective, randomized, parallel-group comparison study, participants receiving DPP-4is were either switched to oral semaglutide (3-14 mg/day) or continued on DPP-4is.
Report a problemFND-3807342206

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.